CN1774423A - 5－(卤代乙酰基)－8－(取代氧基)－(1h)－喹啉－2－酮的制备方法 - Google Patents

5－(卤代乙酰基)－8－(取代氧基)－(1h)－喹啉－2－酮的制备方法 Download PDF

Info

Publication number
CN1774423A
CN1774423A CNA2004800089560A CN200480008956A CN1774423A CN 1774423 A CN1774423 A CN 1774423A CN A2004800089560 A CNA2004800089560 A CN A2004800089560A CN 200480008956 A CN200480008956 A CN 200480008956A CN 1774423 A CN1774423 A CN 1774423A
Authority
CN
China
Prior art keywords
quinoline
hydroxyl
ethanoyl
substituted oxy
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800089560A
Other languages
English (en)
Chinese (zh)
Inventor
O·洛泽
G·佩恩
H·席林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33131902&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1774423(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1774423A publication Critical patent/CN1774423A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
CNA2004800089560A 2003-04-02 2004-04-01 5－(卤代乙酰基)－8－(取代氧基)－(1h)－喹啉－2－酮的制备方法 Pending CN1774423A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45972403P 2003-04-02 2003-04-02
US60/459,724 2003-04-02

Publications (1)

Publication Number Publication Date
CN1774423A true CN1774423A (zh) 2006-05-17

Family

ID=33131902

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800089560A Pending CN1774423A (zh) 2003-04-02 2004-04-01 5－(卤代乙酰基)－8－(取代氧基)－(1h)－喹啉－2－酮的制备方法

Country Status (34)

Country Link
US (1) US7605267B2 (enExample)
EP (1) EP1613599B8 (enExample)
JP (1) JP4726778B2 (enExample)
KR (1) KR101073740B1 (enExample)
CN (1) CN1774423A (enExample)
AR (2) AR043825A1 (enExample)
AT (1) ATE491690T1 (enExample)
AU (1) AU2004226212B2 (enExample)
BR (1) BRPI0409154B1 (enExample)
CA (1) CA2520990C (enExample)
CL (1) CL2004000706A1 (enExample)
CO (1) CO5700779A2 (enExample)
CY (1) CY1111515T1 (enExample)
DE (1) DE602004030553D1 (enExample)
DK (1) DK1613599T3 (enExample)
EC (1) ECSP056059A (enExample)
ES (1) ES2358193T3 (enExample)
HR (1) HRP20110184T1 (enExample)
IL (1) IL171053A (enExample)
IS (1) IS2800B (enExample)
MA (1) MA27761A1 (enExample)
MX (1) MXPA05010616A (enExample)
MY (1) MY141871A (enExample)
NO (1) NO331980B1 (enExample)
NZ (1) NZ542623A (enExample)
PE (2) PE20050211A1 (enExample)
PL (1) PL1613599T3 (enExample)
PT (1) PT1613599E (enExample)
RU (1) RU2339621C2 (enExample)
SI (1) SI1613599T1 (enExample)
TN (1) TNSN05245A1 (enExample)
TW (1) TWI324151B (enExample)
WO (1) WO2004087668A1 (enExample)
ZA (1) ZA200507603B (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102633717A (zh) * 2012-03-30 2012-08-15 西南大学 N-乙酰-喹啉-2(1h)酮类化合物及其制备方法和应用
CN104379566A (zh) * 2012-07-11 2015-02-25 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
CN105693603A (zh) * 2014-11-24 2016-06-22 上海医药工业研究院 改良的马来酸茚达特罗制备工艺
WO2016161956A1 (zh) * 2015-04-09 2016-10-13 正大天晴药业集团股份有限公司 茚达特罗或其盐的制备方法
CN107868045A (zh) * 2016-09-28 2018-04-03 四川海思科制药有限公司 一种茚达特罗中间体的制备方法
CN108264483A (zh) * 2016-12-31 2018-07-10 天津金耀集团有限公司 一种马来酸茚达特罗的制备方法
CN109721534A (zh) * 2018-09-25 2019-05-07 四川海思科制药有限公司 一种马来酸茚达特罗中间体及其制备方法和用途
CN114751857A (zh) * 2022-04-29 2022-07-15 梯尔希（南京）药物研发有限公司 一种茚达特罗杂质的制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) * 2004-06-22 2004-07-28 Novartis Ag Organic compounds
DK2044025T3 (da) 2006-06-30 2013-01-14 Novartis Ag Quinolinonderivater samt farmaceutiske sammensætninger deraf
WO2013132514A2 (en) * 2012-03-09 2013-09-12 Rao Davuluri Ramamohan A novel process for the preparation of (r)-5-[2-[(5, 6-diethyl-2, 3-dihydro-1h-inden-2-yl) amino]-1-hydroxyethyl]-8-hydroxy quinolin-2(1h)-one
CZ306252B6 (cs) 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
PT3092217T (pt) 2014-01-09 2020-09-04 Ramamohan Rao Davuluri Processo inovador para preparação de indacaterol ou dos seus sais farmaceuticamente aceitáveis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS539228B2 (enExample) * 1974-01-31 1978-04-04
CA1164459A (en) * 1980-11-11 1984-03-27 Yung-Hsiung Yang Process for preparing (imidazo¬1,2-a|pyridine- 2-yl)-carbostyril or -3,4-dihydrocarbostyryl derivatives
JPS5896022A (ja) * 1981-11-30 1983-06-07 Otsuka Pharmaceut Co Ltd 強心剤
ES519384A0 (es) * 1983-01-28 1984-03-16 Espanola Farma Therapeut Procedimiento para la obtencion de un compuesto derivado de la 2-quinolinona.
ES8605239A1 (es) * 1985-12-04 1986-03-16 Astur Pharma Un procedimiento para la preparacion de quinolonas sustitui-das
US4894219A (en) * 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
GB9405019D0 (en) * 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
JP2000510865A (ja) * 1996-05-20 2000-08-22 ダーウィン・ディスカバリー・リミテッド Ｔｎｆとｐｄｅ―ｉｖのインヒビターとしてのキノリンカルボキサミド
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI324150B (en) * 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102633717A (zh) * 2012-03-30 2012-08-15 西南大学 N-乙酰-喹啉-2(1h)酮类化合物及其制备方法和应用
CN104379566B (zh) * 2012-07-11 2016-08-24 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
CN104379566A (zh) * 2012-07-11 2015-02-25 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
CN105693603B (zh) * 2014-11-24 2019-11-29 上海医药工业研究院 改良的马来酸茚达特罗制备工艺
CN105693603A (zh) * 2014-11-24 2016-06-22 上海医药工业研究院 改良的马来酸茚达特罗制备工艺
WO2016161956A1 (zh) * 2015-04-09 2016-10-13 正大天晴药业集团股份有限公司 茚达特罗或其盐的制备方法
CN107531636A (zh) * 2015-04-09 2018-01-02 正大天晴药业集团股份有限公司 茚达特罗或其盐的制备方法
CN107531636B (zh) * 2015-04-09 2022-11-25 正大天晴药业集团股份有限公司 茚达特罗或其盐的制备方法
CN107868045A (zh) * 2016-09-28 2018-04-03 四川海思科制药有限公司 一种茚达特罗中间体的制备方法
CN108264483A (zh) * 2016-12-31 2018-07-10 天津金耀集团有限公司 一种马来酸茚达特罗的制备方法
CN109721534A (zh) * 2018-09-25 2019-05-07 四川海思科制药有限公司 一种马来酸茚达特罗中间体及其制备方法和用途
CN109721534B (zh) * 2018-09-25 2022-05-20 四川海思科制药有限公司 一种马来酸茚达特罗中间体及其制备方法和用途
CN114751857A (zh) * 2022-04-29 2022-07-15 梯尔希（南京）药物研发有限公司 一种茚达特罗杂质的制备方法

Also Published As

Publication number Publication date
EP1613599B8 (en) 2011-06-22
TNSN05245A1 (en) 2007-06-11
KR20050119678A (ko) 2005-12-21
ECSP056059A (es) 2006-01-27
HK1086833A1 (en) 2006-09-29
CA2520990C (en) 2011-08-09
DE602004030553D1 (de) 2011-01-27
ZA200507603B (en) 2006-11-29
TWI324151B (en) 2010-05-01
NO20055099D0 (no) 2005-11-01
CA2520990A1 (en) 2004-10-14
US7605267B2 (en) 2009-10-20
CO5700779A2 (es) 2006-11-30
MXPA05010616A (es) 2005-11-23
NZ542623A (en) 2008-07-31
JP2006522055A (ja) 2006-09-28
MY141871A (en) 2010-07-16
PE20050211A1 (es) 2005-04-27
MA27761A1 (fr) 2006-02-01
KR101073740B1 (ko) 2011-10-13
JP4726778B2 (ja) 2011-07-20
SI1613599T1 (sl) 2011-04-29
WO2004087668A1 (en) 2004-10-14
EP1613599A1 (en) 2006-01-11
PL1613599T3 (pl) 2011-05-31
RU2339621C2 (ru) 2008-11-27
US20060189653A1 (en) 2006-08-24
AR043825A1 (es) 2005-08-17
BRPI0409154B1 (pt) 2014-03-25
CL2004000706A1 (es) 2005-01-14
ES2358193T3 (es) 2011-05-06
AU2004226212B2 (en) 2008-02-21
EP1613599B1 (en) 2010-12-15
BRPI0409154A (pt) 2006-03-28
DK1613599T3 (da) 2011-03-28
AR103508A2 (es) 2017-05-17
NO331980B1 (no) 2012-05-21
PT1613599E (pt) 2011-03-17
AU2004226212A1 (en) 2004-10-14
CY1111515T1 (el) 2015-08-05
IL171053A (en) 2010-12-30
TW200504025A (en) 2005-02-01
IS8095A (is) 2005-10-27
ATE491690T1 (de) 2011-01-15
IS2800B (is) 2012-09-15
NO20055099L (no) 2006-01-02
HRP20110184T1 (hr) 2011-04-30
PE20100399A1 (es) 2010-06-01

Similar Documents

Publication Publication Date Title
CN1968927A (zh) 对映体选择性制备喹啉衍生物的方法
CN1094490C (zh) 作为血清素拮抗剂的喹诺－2(1h)－酮衍生物
CN1774423A (zh) 5－(卤代乙酰基)－8－(取代氧基)－(1h)－喹啉－2－酮的制备方法
CN1285578C (zh) 取代苯甲酸酰胺及其在抑制血管生成中的应用
CN1191248C (zh) 作为多巴胺d 受体亚型配体的1－(2－萘基)和1－(2－氮杂萘基)－4－(1－苯基甲基)哌嗪
CN1832927A (zh) 新型γ－分泌酶抑制剂
CN1414969A (zh) 氢化硅烷化反应的催化剂
CN1753874A (zh) 可用作肾上腺素受体激动剂的 5－′( r )－2－( 5 , 6－二乙基－茚满－2－基氨基)－1－羟基－乙基－8－羟基－(1h)－喹啉－2－酮盐的制备方法
CN85104233A (zh) 化学化合物
CN1656075A (zh) 喹啉衍生物和其作为5－ht6配体的用途
CN1320120A (zh) 茚并、萘并和苯并芳庚并二氢噻唑衍生物、它们的制备和它们作为减食欲药物的用途
CN1446218A (zh) 苯并咪唑衍生物,它们的制备方法以及它们的治疗应用
CN87101731A (zh) 8号位上取代的喹诺酮羧酸衍生物及其制备方法
CN1608050A (zh) 哌嗪衍生物
CN1027368C (zh) 新型取代的喹啉衍生物的制备方法
CN1072661C (zh) 新的取代[2－(1－哌嗪基)乙氧基]甲基化合物
CN1062729A (zh) 可用作血管紧张肽转化酶抑制剂的含氨基和硝基的三环新化合物
CN1143861C (zh) 硅烷基-三嗪防晒剂
CN1105358A (zh) N-取代氨杂双环庚烷衍生物，其制备方法以及用途
CN1070403A (zh) 新的-β-咔啉衍生物及其制备和药物应用
CN1199397A (zh) 嘧啶衍生物
CN1164577C (zh) 2-氨基-4-(4-氟苯基)-6-烷基嘧啶-5-羧酸酯的制备方法
CN1791602A (zh) 2－氨基－9－(2－取代乙基)嘌呤及用其制备9－[4－乙酸基－3－(乙酸基甲基)丁烷－1－基]－2－氨基嘌呤的方法
CN1210857A (zh) 三唑衍生物及其盐
CN1308325C (zh) 新的芳基－{4－卤素－4－[(杂芳基甲氨基)甲基]－哌啶－1－基}甲酮衍生物、制备方法及其作为药物的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20060517